Elizabeth A Evans

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4061278/publications.pdf

Version: 2024-02-01

88 papers 3,215 citations

147801 31 h-index 53 g-index

90 all docs 90 docs citations

90 times ranked 3536 citing authors

#	Article	IF	CITATIONS
1	Why Women Veterans Do Not Use VA-Provided Health and Social Services: Implications for Health Care Design and Delivery. Journal of Humanistic Psychology, 2024, 64, 251-280.	2.1	13
2	Predictors of Functioning and Recovery Among Men and Women Veterans with Schizophrenia. Community Mental Health Journal, 2023, 59, 110-121.	2.0	2
3	Longâ€term followâ€up assessment of opioid use outcomes among individuals with comorbid mental disorders and opioid use disorder treated with buprenorphine or methadone in a randomized clinical trial. Addiction, 2022, 117, 151-161.	3.3	8
4	A Scoping Review of Data Sources for the Conduct of Policy-Relevant Substance Use Research. Public Health Reports, 2022, 137, 944-954.	2. 5	4
5	Recidivism and mortality after in-jail buprenorphine treatment for opioid use disorder. Drug and Alcohol Dependence, 2022, 231, 109254.	3.2	40
6	Uncommon and preventable: Perceptions of diversion of medication for opioid use disorder in jail. Journal of Substance Abuse Treatment, 2022, 138, 108746.	2.8	10
7	Legislatively mandated implementation of medications for opioid use disorders in jails: A qualitative study of clinical, correctional, and jail administrator perspectives. Drug and Alcohol Dependence, 2022, 234, 109394.	3.2	12
8	The Massachusetts public health data warehouse and the opioid epidemic: A qualitative study of perceived strengths and limitations for advancing research. Preventive Medicine Reports, 2022, 28, 101847.	1.8	2
9	COVID-19 and treating incarcerated populations for opioid use disorder. Journal of Substance Abuse Treatment, 2021, 124, 108216.	2.8	18
10	Prevalence and Correlates of Cannabis Use in Massachusetts after Cannabis Legalization and before Retail Sales. Journal of Psychoactive Drugs, 2021, 53, 158-167.	1.7	4
11	Massachusetts Justice Community Opioid Innovation Network (MassJCOIN). Journal of Substance Abuse Treatment, 2021, 128, 108275.	2.8	20
12	Psychiatric comorbidity and treatment outcomes in patients with opioid use disorder: Results from a multisite trial of buprenorphine-naloxone and methadone. Drug and Alcohol Dependence, 2021, 228, 108996.	3.2	17
13	Childhood adversity and mental health comorbidity in men and women with opioid use disorders. Addictive Behaviors, 2020, 102, 106149.	3.0	36
14	Changes in Medicaid Acceptance by Substance Abuse Treatment Facilities After Implementation of Federal Parity. Medical Care, 2020, 58, 101-107.	2.4	6
15	A qualitative study of big data and the opioid epidemic: recommendations for data governance. BMC Medical Ethics, 2020, 21, 101.	2.4	11
16	Perceived Benefits and Harms of Involuntary Civil Commitment for Opioid Use Disorder. Journal of Law, Medicine and Ethics, 2020, 48, 718-734.	0.9	6
17	Effects of access barriers and medication acceptability on buprenorphine-naloxone treatment utilization over 2†years: Results from a multisite randomized trial of adults with opioid use disorder. Journal of Substance Abuse Treatment, 2019, 106, 19-28.	2.8	21
18	Criminal justice outcomes over 5 years after randomization to buprenorphineâ€naloxone or methadone treatment for opioid use disorder. Addiction, 2019, 114, 1396-1404.	3.3	32

#	Article	IF	CITATIONS
19	The Natural History, Clinical Course, and Long-Term Recovery from Opioid Use Disorders. Current Clinical Psychiatry, 2019, , 181-196.	0.2	4
20	Psychosocial Factors that Shape Substance Abuse and Related Mental Health of Women Military Veterans who Use Community-Based Services. Substance Use and Misuse, 2018, 53, 1878-1892.	1.4	8
21	Differences by Veteran/civilian status and gender in associations between childhood adversity and alcohol and drug use disorders. Social Psychiatry and Psychiatric Epidemiology, 2018, 53, 421-435.	3.1	24
22	Gender Differences in Use of Complementary and Integrative Health by U.S. Military Veterans with Chronic Musculoskeletal Pain. Women's Health Issues, 2018, 28, 379-386.	2.0	31
23	Cost-Effectiveness of Publicly Funded Treatment of Opioid Use Disorder in California. Annals of Internal Medicine, 2018, 168, 10.	3.9	43
24	Correlates of Long-Term Opioid Abstinence After Randomization to Methadone Versus Buprenorphine/Naloxone in a Multi-Site Trial. Journal of NeuroImmune Pharmacology, 2018, 13, 488-497.	4.1	50
25	The costs of crime during and after publicly funded treatment for opioid use disorders: a populationâ€level study for the state of California. Addiction, 2017, 112, 838-851.	3.3	37
26	Gender differences in the effects of childhood adversity on alcohol, drug, and polysubstance-related disorders. Social Psychiatry and Psychiatric Epidemiology, 2017, 52, 901-912.	3.1	34
27	Gender and race/ethnic differences in the persistence of alcohol, drug, and poly-substance use disorders. Drug and Alcohol Dependence, 2017, 174, 128-136.	3.2	63
28	Estimating State Transitions for Opioid Use Disorders. Medical Decision Making, 2017, 37, 483-497.	2.4	12
29	Polydrug use and its association with drug treatment outcomes among primary heroin, methamphetamine, and cocaine users. International Journal of Drug Policy, 2017, 49, 32-40.	3.3	87
30	Longâ€term outcomes after randomization to buprenorphine/naloxone versus methadone in a multiâ€site trial. Addiction, 2016, 111, 695-705.	3.3	165
31	Gender differences in mortality among treated opioid dependent patients. Drug and Alcohol Dependence, 2015, 155, 228-235.	3.2	39
32	Risk Factors Associated with HCV Among Opioid-Dependent Patients in a Multisite Study. Journal of Community Health, 2015, 40, 940-947.	3.8	12
33	Long-Term Course of Opioid Addiction. Harvard Review of Psychiatry, 2015, 23, 76-89.	2.1	212
34	The Effects of Opioid Substitution Treatment and Highly Active Antiretroviral Therapy on the Cause-Specific Risk of Mortality Among HIV-Positive People Who Inject Drugs. Clinical Infectious Diseases, 2015, 61, 1157-1165.	5.8	48
35	Mortality among individuals accessing pharmacological treatment for opioid dependence in California, 2006–10. Addiction, 2015, 110, 996-1005.	3.3	93
36	Heterogeneity of Mental Health Service Utilization and High Mental Health Service Use Among Women Eight Years After Initiating Substance Use Disorder Treatment. Journal of Substance Abuse Treatment, 2015, 59, 10-19.	2.8	11

#	Article	IF	CITATIONS
37	Maternal Mental Health and Children's Internalizing and Externalizing Behaviors: Beyond Maternal Substance Use Disorders. Journal of Child and Family Studies, 2015, 24, 638-648.	1.3	40
38	Perceived Neighborhood Safety, Recovery Capital, and Successful Outcomes Among Mothers 10 years After Substance Abuse Treatment. Substance Use and Misuse, 2014, 49, 1491-1503.	1.4	15
39	Comparative Effectiveness of California's Proposition 36 and Drug Court Programs Before and After Propensity Score Matching. Crime and Delinquency, 2014, 60, 909-938.	1.7	19
40	Commentary on Degenhardt <i>et al</i> . (2014): Regional variation in the global burden of disease attributable to opioid dependenceâ€"where do the data come from and does population size matter?. Addiction, 2014, 109, 1334-1335.	3.3	3
41	Children of treated substance-abusing mothers: A 10-year prospective study. Clinical Child Psychology and Psychiatry, 2014, 19, 217-232.	1.6	16
42	Utilization and outcomes of detoxification and maintenance treatment for opioid dependence in publicly-funded facilities in California, USA: 1991–2012. Drug and Alcohol Dependence, 2014, 143, 149-157.	3.2	29
43	Characterizing longitudinal health state transitions among heroin, cocaine, and methamphetamine users. Drug and Alcohol Dependence, 2014, 140, 69-77.	3.2	23
44	Developmental timing of first drug treatment and 10-year patterns of drug use. Journal of Substance Abuse Treatment, 2013, 44, 271-279.	2.8	20
45	Explaining long-term outcomes among drug dependent mothers treated in women-only versus mixed-gender programs. Journal of Substance Abuse Treatment, 2013, 45, 293-301.	2.8	30
46	Consistency in Self-Reports of Drug Use Frequency by High-Risk Offenders Over a 5-Year Interval. Prison Journal, 2013, 93, 375-389.	0.7	5
47	Offender Diversion Into Substance Use Disorder Treatment: The Economic Impact of California's Proposition 36. American Journal of Public Health, 2013, 103, 1096-1102.	2.7	29
48	Hepatitis C among methadone maintenance treatment patients in Shanghai and Kunming, China. Journal of Public Health, 2012, 34, 24-31.	1.8	12
49	More Alike than Different: Health Needs, Services Utilization, and Outcomes of Asian American and Pacific Islander (AAPI) Populations Treated for Substance Use Disorders. Journal of Ethnicity in Substance Abuse, 2012, 11, 318-338.	0.9	14
50	Differential Outcomes of Court-Supervised Substance Abuse Treatment Among California Parolees and Probationers. International Journal of Offender Therapy and Comparative Criminology, 2012, 56, 539-556.	1,2	25
51	A mixed methods approach to identifying factors related to voluntary HIV testing among injection drug users in Shanghai, China. International Journal of Infectious Diseases, 2012, 16, e498-e503.	3.3	19
52	Hispanic parenting women in women-only versus mixed-gender drug treatment: A 10-year prospective study. Addictive Behaviors, 2012, 37, 729-735.	3.0	1
53	Mortality among substanceâ€using mothers in California: a 10â€year prospective study. Addiction, 2012, 107, 215-222.	3.3	36
54	Defining dosing pattern characteristics of successful tapers following methadone maintenance treatment: results from a populationâ€based retrospective cohort study. Addiction, 2012, 107, 1621-1629.	3.3	59

#	Article	IF	CITATIONS
55	Long-term outcomes among drug-dependent mothers treated in women-only versus mixed-gender programs. Journal of Substance Abuse Treatment, 2011, 41, 115-123.	2.8	39
56	Effects of a randomized contingency management intervention on opiate abstinence and retention in methadone maintenance treatment in China. Addiction, 2011, 106, 1801-1809.	3.3	62
57	Employment trajectories: Exploring gender differences and impacts of drug use. Journal of Vocational Behavior, 2011, 79, 277-289.	3.4	50
58	Promising practices for delivery of court-supervised substance abuse treatment: Perspectives from six high-performing California counties operating Proposition 36. Evaluation and Program Planning, 2011, 34, 124-134.	1.6	13
59	High-Risk Offenders Participating in Court-Supervised Substance Abuse Treatment: Characteristics, Treatment Received, and Factors Associated with Recidivism. Journal of Behavioral Health Services and Research, 2011, 38, 510-525.	1.4	25
60	Using Administrative Data for Longitudinal Substance Abuse Research. Journal of Behavioral Health Services and Research, 2010, 37, 252-271.	1.4	56
61	Employment Services Utilization and Outcomes among Substance Abusing Offenders Participating in California's Proposition 36 Drug Treatment Initiative. Journal of Behavioral Health Services and Research, 2010, 37, 461-476.	1.4	12
62	Are There Gender Differences in Arrest Trajectories among Adult Drug Abuse Treatment Participants?. Journal of Drug Issues, 2010, 40, 7-26.	1.2	9
63	A Marginal Structural Modeling Approach to Assess the Cumulative Effect of Drug Treatment on Later Drug Use Abstinence. Journal of Drug Issues, 2010, 40, 221-240.	1.2	17
64	Accuracy of amplitude integrated EEG in a neonatal cohort. Archives of Disease in Childhood: Fetal and Neonatal Edition, 2010, 95, F169-F173.	2.8	66
65	Client and program factors associated with dropout from court mandated drug treatment. Evaluation and Program Planning, 2009, 32, 204-212.	1.6	102
66	Predictors of Intention to Change HIV Sexual and Injection Risk Behaviors among Heterosexual Methamphetamine-Using Offenders in Drug Treatment: A Test of the AIDS Risk Reduction Model. Journal of Behavioral Health Services and Research, 2009, 36, 247-266.	1.4	9
67	Cross-system data linkage for treatment outcome evaluation: Lessons learned from the California Treatment Outcome Project. Evaluation and Program Planning, 2008, 31, 125-135.	1.6	42
68	Treatment entry barriers among California's Proposition 36 offenders. Journal of Substance Abuse Treatment, 2008, 35, 410-418.	2.8	19
69	Comparing the dynamic course of heroin, cocaine, and methamphetamine use over 10Âyears. Addictive Behaviors, 2008, 33, 1581-1589.	3.0	75
70	Polydrug use and implications for longitudinal research: Ten-year trajectories for heroin, cocaine, and methamphetamine users. Drug and Alcohol Dependence, 2008, 96, 193-201.	3.2	94
71	Regulatory Issues Encountered When Conducting Longitudinal Substance Abuse Research. Journal of Drug Issues, 2008, 38, 1003-1025.	1.2	6
72	Longitudinal HIV Risk Behavior Among the Drug Abuse Treatment Outcome Studies (DATOS) Adult Sample. Evaluation Review, 2008, 32, 83-112.	1.0	12

#	Article	IF	CITATIONS
73	Contrasting Trajectories of Heroin, Cocaine, and Methamphetamine Use. Journal of Addictive Diseases, 2008, 27, 13-21.	1.3	106
74	Impact of California's Proposition 36 on the Drug Treatment System: Treatment Capacity and Displacement. American Journal of Public Health, 2007, 97, 104-109.	2.7	53
75	Ethnic differences in utilization of drug treatment services and outcomes among Proposition 36 offenders in California. Journal of Substance Abuse Treatment, 2007, 33, 391-399.	2.8	24
76	Predictors of short-term treatment outcomes among California's Proposition 36 participants. Evaluation and Program Planning, 2007, 30, 187-196.	1.6	13
77	Evaluation of the Substance Abuse and Crime Prevention Act: Client Characteristics, Treatment Completion and Re-Offending Three Years After Implementation. Journal of Psychoactive Drugs, 2006, 38, 357-367.	1.7	15
78	Outcomes of Drug and Alcohol Treatment Programs Among American Indians in California. American Journal of Public Health, 2006, 96, 889-896.	2.7	40
79	Benefit-Cost in the California Treatment Outcome Project: Does Substance Abuse Treatment "Pay for Itself"?. Health Services Research, 2006, 41, 192-213.	2.0	140
80	Implementation of a Statewide Outcome Monitoring System: Lessons Learned From Substance Abuse Treatment Provider Staff. Qualitative Health Research, 2006, 16, 337-352.	2.1	10
81	Utilization and Outcomes of Mental Health Services Among Patients in Drug Treatment. Journal of Addictive Diseases, 2006, 25, 73-85.	1.3	14
82	How Can Research-Based Findings Be Used to Improve Practice? Perspectives from Participants in a Statewide Outcomes Monitoring Study. Journal of Drug Issues, 2005, 35, 469-483.	1.2	1
83	Treatment outcomes among women and men methamphetamine abusers in California. Journal of Substance Abuse Treatment, 2005, 28, 77-85.	2.8	169
84	Evaluation of the Substance Abuse and Crime Prevention Act: Treatment Clients and Program Types During the First Year of Implementation. Journal of Psychoactive Drugs, 2004, 36, 165-174.	1.7	15
85	Relationship Between Drug Treatment Services, Retention, and Outcomes. Psychiatric Services, 2004, 55, 767-774.	2.0	209
86	Pilot-Testing a Statewide Outcome Monitoring System: Overview of the California Treatment Outcome Project (CALTOP). Journal of Psychoactive Drugs, 2004, 36, 109-114.	1.7	28
87	Treating Drug-Abusing Offenders. Evaluation Review, 2003, 27, 479-505.	1.0	39
88	Commentary on Adams $\langle i \rangle$ et al $\langle i \rangle$.: using administrative big data for the public good. Addiction, 0, , .	3.3	1